Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy: Basic Science

In vivo evaluation of [F-18]-labeled 3,5-bis(2-fluorobenzylidene)-4-piperidone as an imageable antiproliferative agent

Vibhudutta Awasthi, Pallavi Lagisetty and Kaustuv Sahoo
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 194;
Vibhudutta Awasthi
1OUHSC, Oklahoma City, OK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pallavi Lagisetty
1OUHSC, Oklahoma City, OK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaustuv Sahoo
1OUHSC, Oklahoma City, OK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 52 no. supplement 1 194

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online November 4, 2014.

Copyright & Usage 
© 2011

Author Information

  1. Vibhudutta Awasthi1,
  2. Pallavi Lagisetty1 and
  3. Kaustuv Sahoo1
  1. 1OUHSC, Oklahoma City, OK

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: November 2014 to April 2025

AbstractFullPdf
Nov 2014100
Apr 2015500
Jun 2015400
Jul 2015300
Aug 2015200
Sep 2015500
Jan 2016900
Feb 2016100
Apr 2016200
Jun 2016100
Jul 2016400
Aug 2016200
Sep 2016200
Nov 2016300
Dec 2016100
Jan 2017200
Apr 2017100
Jun 2017100
Jul 2017100
Aug 2017100
Sep 2017100
Oct 2017100
Jan 2018200
May 2018100
Sep 2018300
Jun 2019100
Jan 2020300
Feb 2020400
Mar 20201400
Apr 2020900
Jun 2020100
Jul 2020400
Aug 20201600
Sep 20203300
Oct 20201700
Nov 20202000
Dec 20201200
Jan 2021200
Feb 20211400
Mar 20211100
Apr 2021900
May 2021400
Jun 2021100
Jul 20211400
Aug 20213600
Sep 20211300
Oct 20211200
Nov 20219100
Dec 20214100
Jan 20227900
Feb 20222500
Mar 20221300
Apr 20222400
May 20222800
Jun 2022300
Aug 2022200
Sep 2022100
Nov 2022100
Mar 2023300
Apr 2023300
May 2023100
Jun 2023100
Jul 2023200
Aug 2023300
Sep 2023200
Oct 2023300
Nov 2023200
Dec 2023100
Jan 2024300
Feb 2024100
Mar 2024100
Apr 2024100
May 2024100
Jun 2024400
Jul 2024100
Aug 2024200
Sep 2024700
Nov 2024300
Dec 2024500
Jan 2025100
Mar 2025300
Apr 2025300
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 52, Issue supplement 1
May 2011
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In vivo evaluation of [F-18]-labeled 3,5-bis(2-fluorobenzylidene)-4-piperidone as an imageable antiproliferative agent
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
In vivo evaluation of [F-18]-labeled 3,5-bis(2-fluorobenzylidene)-4-piperidone as an imageable antiproliferative agent
Vibhudutta Awasthi, Pallavi Lagisetty, Kaustuv Sahoo
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 194;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In vivo evaluation of [F-18]-labeled 3,5-bis(2-fluorobenzylidene)-4-piperidone as an imageable antiproliferative agent
Vibhudutta Awasthi, Pallavi Lagisetty, Kaustuv Sahoo
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 194;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy: Basic Science

  • Modification of chemical structure to improve biodistribution of a radiolabeled sigma ligand for tumor-imaging
  • A Cy5** labelled anti-EGFR affibody selectively targets EGFR in mouse xenograft model
  • Functional analysis of adenoviral induced HSV-TK expression using a breast cancer-specific vs. a non-specific promoter
Show more Oncology: Basic, Translational & Therapy: Basic Science

Basic Science II (Oncology): Peptides/Small Molecules

  • Modification of chemical structure to improve biodistribution of a radiolabeled sigma ligand for tumor-imaging
  • A Cy5** labelled anti-EGFR affibody selectively targets EGFR in mouse xenograft model
  • Functional analysis of adenoviral induced HSV-TK expression using a breast cancer-specific vs. a non-specific promoter
Show more Basic Science II (Oncology): Peptides/Small Molecules

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire